Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 96-103

  Savale, Laurent ^a,b,c   Magnier, Romain ^d   Le Pavec, Jérôme ^a,b,c   Jaïs, Xavier ^a,b,c   Montani, David ^a,b,c   O'Callaghan, Dermot S ^a,b,c   Humbert, Marc ^a,b,c   Dingemanse, Jasper ^e   Simonneau, Gérald ^a,b,c   Sitbon, Olivier ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Bosentan; Cirrhosis; Endothelin receptor antagonists; Hypertension; Portopulmonary hypertension; Pulmonary

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LIVER CIRRHOSIS; LUNG HEMODYNAMICS; MALE; OUTCOME ASSESSMENT; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYNDROME DELINEATION;

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PORTAL SYSTEM; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 84871234372     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00117511     Document Type: Article

References (39)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
2. Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528.
3. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409.
4. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-1468.
5. Halank M, Ewert R, Seyfarth HJ, et al. Portopulmonary hypertension. J Gastroenterol 2006; 41: 837-847.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
7. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637-643.
8. Robalino BD. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498.
9. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111.
10. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141: 906-915.
11. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
12. Halank M, Miehlke S, Hoeffken G, et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-1776.
13. Grander W, Eller P, Fuschelberger R, et al. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36: Suppl. 3, 67-70.
14. Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2: 1039-1042.
15. Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006; 36: Suppl. 3, 54-61.
16. Stahler G, von Hunnius P. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36: Suppl. 3, 62-66.
17. Barth F, Gerber PJ, Reichen J, et al. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol 2006; 18: 1117-1119.
18. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128: 164-168.
19. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102.
20. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508.
21. van Giersbergen PL, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan., a dual endothelin receptor antagonist. J Clin Pharmacol 2003; 43: 15-22.
22. Rodriguez-Roisin R, Krowka MJ, Herve P, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861-880.
23. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
24. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
25. Cohen H, Chahine C, Hui A, et al. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004; 61: 1107-1119.
26. Dell D, Lausecker B, Hopfgartner G, et al. Evolving bioanalytical methods for the cardiovascular drug bosentan. Chromatographia 2002; 55: S115-S119.
27. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-1115.
28. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262-263.
29. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
30. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
31. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33: 92-98.
32. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
33. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362.
34. Chan CC, Wang SS, Lee FY, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001; 33: 816-820.
35. Kojima H, Sakurai S, Kuriyama S, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001; 34: 805-811.
36. Tieche S, De Gottardi A, Kappeler A, et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 2001; 34: 38-45.
37. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344.
38. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139: 109-114.
39. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective study. Ann Intern Med 1991; 115: 343-349.